

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**KELUN-BIOTECH**  
**科伦博泰**

**Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.**  
**四川科倫博泰生物醫藥股份有限公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock Code: 6990)**

**VOLUNTARY ANNOUNCEMENT**  
**RECEIPT OF PAYMENT MADE BY MEDILINK THERAPEUTICS**  
**PURSUANT TO THE SETTLEMENT**

Reference is made to the announcement (the “**Announcement**”) of the Company dated December 16, 2025 in relation to the entry into a settlement agreement with MediLink Therapeutics (Suzhou) Co., Ltd. (“**MediLink Therapeutics**”), Dr. Xue Tongtong, Dr. Xiao Liang and Dr. Jia Qiang Cai. Unless otherwise defined, capitalized terms used herein shall have the same meanings as those defined in the Announcement.

The Board hereby announces that the Company has recently received from MediLink Therapeutics the shared income of RMB602,509,600.00 generated from the out-licensing of YL201 pursuant to the Settlement. For the year of 2026 and as of the date of this announcement, the Company has received from MediLink Therapeutics an aggregate amount of RMB702,721,325.78 (including the above-mentioned RMB602,509,600.00) pursuant to the Settlement.

**THE COMPANY’S SHAREHOLDERS AND POTENTIAL INVESTORS ARE REMINDED TO EXERCISE CAUTION WHEN DEALING IN THE SECURITIES OF THE COMPANY.**

By order of the Board

**Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.**  
**LIU Gexin**

*Chairman of the Board and Non-executive Director*

Hong Kong, June 12, 2026

*As at the date of this announcement, the Board comprises Mr. LIU Gexin as the chairman of the Board and non-executive Director, Dr. GE Junyou as executive Director, Mr. LIU Sichuan, Mr. LAI Degui, Mr. FENG Hao, Ms. LIAO Yihong and Mr. ZENG Xuebo as non-executive Directors, and Dr. ZHENG Qiang, Dr. TU Wenwei, Dr. JIN Jinping and Dr. LI Yuedong as independent non-executive Directors.*